In a regulatory filing, Sarepta Therapeutics president and CEO Douglas S. Ingram disclosed the acquisition of 16,695 common shares of the company in two transactions. The first transaction of 13,561 shares was bought at $120.26 per share, while the second transaction of 3,134 shares was bought at $120.94 per share.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.